Sie suchten nach: invasive (Griechisch - Englisch)

secondline treatment of invasive aspergillosis
j02ax04 secondline treatment of invasive aspergillosis

"global invasive species database".
"global invasive species database".

Ανακτήθηκε 26 Δεκεμβρίου 2006* invasive species specialist group (issg).
* invasive species specialist group (issg).

points to consider on the evaluation of new anti- fungal agents for invasive fungal infections.
fibrin sealants note for guidance on the clinical investigation of von willebrand factor warning on transmissible agents for patient leaflets and spcs core spc for plasma derived fibrin sealants

prevention of invasive infections due to vancomycin resistant enterococci (vre) in colonised patients deemed
prevention of invasive infections due to vancomycin resistant

j07al active immunisation of infants and children against invasive disease, pneumonia and otitis media caused by streptococcus pneumoniae
- j07al - active immunisation of infants and children against invasive disease, pneumonia and otitis media caused by streptococcus pneumoniae

concept paper on the development of a cpmp points to consider document on the evaluation of new anti- fungal agents for invasive fungal infections
concept paper on the development of a cpmp points to consider document on the evaluation of new anti-fungal agents for invasive fungal infections

actions will aim to control invasive species and strengthen the conservation status of emys orbicularis, mauremys leprosa, barbus meridionalis and unio elongatulus.
actions will aim to control invasive species and strengthen the conservation status of emys orbicularis , m auremys leprosa , barbus meridionalis and unio elongatulus .

the project aims to eradicate two of the three invasive alien species that are currently impacting local biodiversity on the island of montecristo - rattus rattus and ailanthus altissima.
the project aims to eradicate two of the three invasive alien species that are currently impacting local biodiversity on the island of montecristo - rattus rattus and ailanthus altissima .

Η προφύλαξη θα πρέπει να είναι όσο το δυνατόν συντομότερη ανάλογα με τον κίνδυνο ανάπτυξης διηθητικής μυκητιασικής λοίμωξης (invasive fungal infection, ifi), όπως καθορίζεται από την ουδετεροπενία ή την ανοσοκαταστολή.
prophylaxis should be as short as possible depending on the risk for developing invasive fungal infection (ifi) as defined by neutropenia or immunosuppression.

adjustment for baseline covariates points to consider on the clinical investigation of medicinal products in the treatment of asthma note for guidance on the clinical investigation of medicinal products for the treatment of urinary incontinence in women note for guidance on the evaluation of medicinal products for treatment of migraine appendix to the cpmp note for guidance on the clinical investigation of medicinal products in the treatment of schizophrenia, on methodology of clinical trials concerning the development of depot preparations of approved medicinal products in schizophrenia note for guidance on the evaluation of medicinal products indicated for thrombolysis in acute myocardial infarction addendum on acute cardiac failure to the cpmp note for guidance on clinical investigation of medicinal products in the treatment of acute cardiac failure note for guidance on the evaluation of medicinal products for the treatment of dyslipoproteinaemia points to consider on clinical investigation of slow- acting anti- rheumatic medicinal products in rheumatoid arthritis points to consider on irritable bowel syndrome points to consider document on the evaluation of new anti- fungal agents for invasive fungal infections points to consider on biostatistical/ methodological issues arising from cpmp discussion on licensing applications:
adjustment for baseline covariates points to consider on the clinical investigation of medicinal products in the treatment of asthma note for guidance on the clinical investigation of medicinal products for the treatment of urinary incontinence in women note for guidance on the evaluation of medicinal products for treatment of migraine appendix to the cpmp note for guidance on the clinical investigation of medicinal products in the treatment of schizophrenia, on methodology of clinical trials concerning the development of depot preparations of approved medicinal products in schizophrenia note for guidance on the evaluation of medicinal products indicated for thrombolysis in acute myocardial infarction addendum on acute cardiac failure to the cpmp note for guidance on clinical investigation of medicinal products in the treatment of acute cardiac failure note for guidance on the evaluation of medicinal products for the treatment of dyslipoproteinaemia points to consider on clinical investigation of slow-acting anti-rheumatic medicinal products in rheumatoid arthritis points to consider on irritable bowel syndrome points to consider document on the evaluation of new anti-fungal agents for invasive fungal infections points to consider on biostatistical/ methodological issues arising from cpmp discussion on licensing applications: